JP2018503373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503373A5 JP2018503373A5 JP2017534648A JP2017534648A JP2018503373A5 JP 2018503373 A5 JP2018503373 A5 JP 2018503373A5 JP 2017534648 A JP2017534648 A JP 2017534648A JP 2017534648 A JP2017534648 A JP 2017534648A JP 2018503373 A5 JP2018503373 A5 JP 2018503373A5
- Authority
- JP
- Japan
- Prior art keywords
- expression level
- determined
- cancer
- correlates
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 IFNγ Proteins 0.000 claims 26
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 20
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 16
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 15
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 15
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 14
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 14
- 102100030386 Granzyme A Human genes 0.000 claims 14
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 14
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 14
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims 14
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 14
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 14
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 14
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 14
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 14
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 13
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 13
- 238000009169 immunotherapy Methods 0.000 claims 13
- 108010017009 CD11b Antigen Proteins 0.000 claims 12
- 108010009992 CD163 antigen Proteins 0.000 claims 12
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 12
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 12
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 12
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 12
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 12
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 12
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 12
- 102100022338 Integrin alpha-M Human genes 0.000 claims 12
- 102100022297 Integrin alpha-X Human genes 0.000 claims 12
- 102000017578 LAG3 Human genes 0.000 claims 12
- 102100025136 Macrosialin Human genes 0.000 claims 12
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 12
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 claims 12
- 239000005557 antagonist Substances 0.000 claims 12
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 11
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 210000002865 immune cell Anatomy 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 10
- 230000004547 gene signature Effects 0.000 claims 10
- 102100038077 CD226 antigen Human genes 0.000 claims 8
- 102100027207 CD27 antigen Human genes 0.000 claims 8
- 102100038078 CD276 antigen Human genes 0.000 claims 8
- 102100030751 Eomesodermin homolog Human genes 0.000 claims 8
- 102100030385 Granzyme B Human genes 0.000 claims 8
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 8
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 8
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 8
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 claims 8
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 claims 8
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 claims 8
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 8
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 8
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 8
- 102100028467 Perforin-1 Human genes 0.000 claims 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 8
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 8
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 8
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 8
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 8
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 8
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 claims 7
- 102100029740 Poliovirus receptor Human genes 0.000 claims 7
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 6
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims 6
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 claims 6
- 102100024358 Arf-GAP with dual PH domain-containing protein 2 Human genes 0.000 claims 6
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 6
- 102100030401 Biglycan Human genes 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 6
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 6
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 6
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 6
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 6
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims 6
- 101150013553 CD40 gene Proteins 0.000 claims 6
- 102100036008 CD48 antigen Human genes 0.000 claims 6
- 102100025221 CD70 antigen Human genes 0.000 claims 6
- 102100022145 Collagen alpha-1(IV) chain Human genes 0.000 claims 6
- 102100031457 Collagen alpha-1(V) chain Human genes 0.000 claims 6
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 claims 6
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 6
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims 6
- 101150032879 Fcrl5 gene Proteins 0.000 claims 6
- 102100037362 Fibronectin Human genes 0.000 claims 6
- 102100020997 Fractalkine Human genes 0.000 claims 6
- 101710088083 Glomulin Proteins 0.000 claims 6
- 102100021186 Granulysin Human genes 0.000 claims 6
- 102100038393 Granzyme H Human genes 0.000 claims 6
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims 6
- 101000832784 Homo sapiens Arf-GAP with dual PH domain-containing protein 2 Proteins 0.000 claims 6
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 6
- 101001126865 Homo sapiens Biglycan Proteins 0.000 claims 6
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims 6
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 6
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 6
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 6
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 6
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims 6
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims 6
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 6
- 101000901150 Homo sapiens Collagen alpha-1(IV) chain Proteins 0.000 claims 6
- 101000941708 Homo sapiens Collagen alpha-1(V) chain Proteins 0.000 claims 6
- 101000909492 Homo sapiens Collagen alpha-1(VIII) chain Proteins 0.000 claims 6
- 101000710876 Homo sapiens Collagen alpha-2(IV) chain Proteins 0.000 claims 6
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 6
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims 6
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims 6
- 101001040751 Homo sapiens Granulysin Proteins 0.000 claims 6
- 101001033000 Homo sapiens Granzyme H Proteins 0.000 claims 6
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 6
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 6
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 claims 6
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims 6
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 6
- 101001051291 Homo sapiens Lysosomal-associated transmembrane protein 5 Proteins 0.000 claims 6
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims 6
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 6
- 101001134216 Homo sapiens Macrophage scavenger receptor types I and II Proteins 0.000 claims 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 6
- 101001059802 Homo sapiens N-formyl peptide receptor 3 Proteins 0.000 claims 6
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 6
- 101001109470 Homo sapiens NKG2-E type II integral membrane protein Proteins 0.000 claims 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 6
- 101000652382 Homo sapiens O-phosphoseryl-tRNA(Sec) selenium transferase Proteins 0.000 claims 6
- 101000600766 Homo sapiens Podoplanin Proteins 0.000 claims 6
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims 6
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 6
- 101000979599 Homo sapiens Protein NKG7 Proteins 0.000 claims 6
- 101000639063 Homo sapiens Protein UXT Proteins 0.000 claims 6
- 101000937675 Homo sapiens Putative uncharacterized protein FAM30A Proteins 0.000 claims 6
- 101000648042 Homo sapiens Signal-transducing adaptor protein 1 Proteins 0.000 claims 6
- 101000689199 Homo sapiens Src-like-adapter Proteins 0.000 claims 6
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 claims 6
- 101000634846 Homo sapiens T-cell receptor-associated transmembrane adapter 1 Proteins 0.000 claims 6
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 6
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 claims 6
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 6
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 claims 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 6
- 101000649068 Homo sapiens Tapasin Proteins 0.000 claims 6
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims 6
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 6
- 108091058560 IL8 Proteins 0.000 claims 6
- 102100039065 Interleukin-1 beta Human genes 0.000 claims 6
- 102100033461 Interleukin-17A Human genes 0.000 claims 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 6
- 102000004889 Interleukin-6 Human genes 0.000 claims 6
- 108090001005 Interleukin-6 Proteins 0.000 claims 6
- 102000004890 Interleukin-8 Human genes 0.000 claims 6
- 108090001007 Interleukin-8 Proteins 0.000 claims 6
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 claims 6
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims 6
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 6
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 6
- 102100024625 Lysosomal-associated transmembrane protein 5 Human genes 0.000 claims 6
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims 6
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 6
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 claims 6
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 claims 6
- 108010031099 Mannose Receptor Proteins 0.000 claims 6
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 6
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 6
- 102100028130 N-formyl peptide receptor 3 Human genes 0.000 claims 6
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 6
- 102100022701 NKG2-E type II integral membrane protein Human genes 0.000 claims 6
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 6
- 102000036938 POU2AF1 Human genes 0.000 claims 6
- 108060006456 POU2AF1 Proteins 0.000 claims 6
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 6
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 6
- 102100037265 Podoplanin Human genes 0.000 claims 6
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 6
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 6
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims 6
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 6
- 102100023370 Protein NKG7 Human genes 0.000 claims 6
- 102100027323 Putative uncharacterized protein FAM30A Human genes 0.000 claims 6
- 102100025263 Signal-transducing adaptor protein 1 Human genes 0.000 claims 6
- 102100024519 Src-like-adapter Human genes 0.000 claims 6
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 claims 6
- 102100029453 T-cell receptor-associated transmembrane adapter 1 Human genes 0.000 claims 6
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 6
- 102100036014 T-cell surface glycoprotein CD1c Human genes 0.000 claims 6
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 6
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 claims 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 6
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 claims 6
- 102100028082 Tapasin Human genes 0.000 claims 6
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims 6
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 claims 6
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 6
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 claims 6
- 102100024337 Collagen alpha-1(VIII) chain Human genes 0.000 claims 5
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims 5
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims 5
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 claims 5
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 claims 5
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 claims 5
- 102100033454 Interleukin-17F Human genes 0.000 claims 5
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 102000004506 Blood Proteins Human genes 0.000 claims 2
- 108010017384 Blood Proteins Proteins 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 2
- 108020003285 Isocitrate lyase Proteins 0.000 claims 2
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 206010038111 Recurrent cancer Diseases 0.000 claims 2
- 206010070308 Refractory cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000001461 cytolytic effect Effects 0.000 claims 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 108091008039 hormone receptors Proteins 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 239000010445 mica Substances 0.000 claims 2
- 229910052618 mica group Inorganic materials 0.000 claims 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 claims 1
- 101150000555 FOX3 gene Proteins 0.000 claims 1
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims 1
- 101000998181 Homo sapiens Interleukin-17B Proteins 0.000 claims 1
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims 1
- 102100033101 Interleukin-17B Human genes 0.000 claims 1
- 210000004322 M2 macrophage Anatomy 0.000 claims 1
- 101100313649 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) POT1 gene Proteins 0.000 claims 1
- 230000009809 T cell chemotaxis Effects 0.000 claims 1
- 210000000068 Th17 cell Anatomy 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 108091008034 costimulatory receptors Proteins 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021031306A JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098055P | 2014-12-30 | 2014-12-30 | |
| US62/098,055 | 2014-12-30 | ||
| PCT/US2015/067878 WO2016109546A2 (en) | 2014-12-30 | 2015-12-29 | Methods and compositions for prognosis and treatment of cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031306A Division JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018503373A JP2018503373A (ja) | 2018-02-08 |
| JP2018503373A5 true JP2018503373A5 (enExample) | 2019-01-31 |
Family
ID=55315702
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534648A Pending JP2018503373A (ja) | 2014-12-30 | 2015-12-29 | がんの予後診断及び治療のための方法及び組成物 |
| JP2021031306A Active JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031306A Active JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11236394B2 (enExample) |
| EP (1) | EP3240908A2 (enExample) |
| JP (2) | JP2018503373A (enExample) |
| CN (1) | CN107208138A (enExample) |
| WO (1) | WO2016109546A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| EP3400246B1 (en) | 2016-01-08 | 2020-10-21 | H. Hoffnabb-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| WO2018029124A1 (en) * | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| JP7235508B2 (ja) * | 2016-11-24 | 2023-03-08 | 第一三共株式会社 | Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法 |
| CN110662552A (zh) | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | 包含tigit结合剂的癌症治疗方法 |
| EP3333268A1 (en) * | 2016-12-09 | 2018-06-13 | Institut Paoli Calmettes | Biomarker panel for prognosis of bladder cancer |
| WO2018122249A1 (en) * | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer |
| EP3580349A1 (en) * | 2017-02-07 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tim-3 for assessing the severity of cancer |
| CN106950371B (zh) * | 2017-02-17 | 2019-03-08 | 张灏 | Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途 |
| EP3589754B1 (en) | 2017-03-01 | 2023-06-28 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
| US10340030B2 (en) | 2017-06-13 | 2019-07-02 | Bostongene Corporation | Systems and methods for identifying cancer treatments from normalized biomarker scores |
| KR102348291B1 (ko) * | 2017-06-14 | 2022-01-07 | 연세대학교 산학협력단 | 암 환자의 치료 반응성을 예측하는 방법 |
| WO2018232142A1 (en) * | 2017-06-14 | 2018-12-20 | Icahn School Of Medicine At Mount Sinai | Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy |
| CN111164700B (zh) * | 2017-07-14 | 2024-10-29 | 余因子基因组学公司 | 使用下一代测序的免疫-肿瘤学应用 |
| JP7304558B2 (ja) * | 2017-12-12 | 2023-07-07 | 地方独立行政法人神奈川県立病院機構 | がん免疫療法の予後予測のためのバイオマーカー |
| CN112771177A (zh) * | 2018-05-21 | 2021-05-07 | 纳米线科技公司 | 分子基因标签及其使用方法 |
| CN108823309B (zh) * | 2018-06-11 | 2021-11-30 | 北京大学人民医院 | 检测kiaa0125基因表达水平的物质在辅助鉴定急性淋巴细胞白血病中的应用 |
| GB201810190D0 (en) * | 2018-06-21 | 2018-08-08 | Cancer Research Tech Ltd | Prognostic and treatment response predictive method |
| EP3833323A4 (en) * | 2018-08-08 | 2022-08-10 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer and autoimmune diseases |
| KR102084196B1 (ko) * | 2018-08-29 | 2020-03-03 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| US20210338727A1 (en) * | 2018-09-13 | 2021-11-04 | Nkarta, Inc. | Natural killer cell compositions and immunotherapy methods for treating tumors |
| KR20210100656A (ko) * | 2018-12-05 | 2021-08-17 | 제넨테크, 인크. | 암 면역요법을 위한 진단 방법 및 조성물 |
| CA3131533A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN109880894A (zh) * | 2019-03-05 | 2019-06-14 | 杭州西合森医学检验实验室有限公司 | 基于RNAseq的肿瘤免疫微环境预测模型的构建方法 |
| WO2020201362A2 (en) * | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| EP3953712A1 (en) * | 2019-04-10 | 2022-02-16 | Universität Zürich | A method for determining the likelihood of a patient being responsive to cancer immunotherapy |
| JP2022534967A (ja) * | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
| EP3976040A1 (en) * | 2019-06-01 | 2022-04-06 | Ares Trading S.A. | Pd-1 axis binding antagonist to treat cancer with genetic mutations in specific genes |
| KR102042710B1 (ko) * | 2019-07-02 | 2019-11-08 | 의료법인 성광의료재단 | 면역체크 포인트와 관련된, 난소암 진단용 바이오마커 |
| CN110804642B (zh) * | 2019-09-10 | 2022-06-21 | 清华大学 | Gpr174免疫学功能及其用途 |
| KR20210068304A (ko) * | 2019-11-29 | 2021-06-09 | 의료법인 성광의료재단 | 면역 세포 치료제에 대한 치료 반응성 예측용 바이오마커 |
| US20210181200A1 (en) * | 2019-12-17 | 2021-06-17 | Women's College Hospital | Ovarian cancer biomarker and methods of using same |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| KR20230012559A (ko) | 2020-05-19 | 2023-01-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 결합 분자 |
| CN111500733B (zh) * | 2020-05-27 | 2022-03-08 | 中国人民解放军军事科学院军事医学研究院 | 外周血单核细胞中用于非小细胞肺癌早期诊断的分子标记物 |
| AU2021293507A1 (en) | 2020-06-18 | 2023-02-02 | F. Hoffmann-La Roche Ag | Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists |
| KR102647295B1 (ko) * | 2020-09-03 | 2024-03-14 | 한국과학기술연구원 | 암 면역 치료의 효능 예측을 위한 바이오마커 및 이의 용도 |
| WO2022053065A1 (zh) * | 2020-09-14 | 2022-03-17 | 信达生物制药(苏州)有限公司 | 用于预测或评估肺癌患者的生物标志物、检测方法及应用 |
| WO2022109607A2 (en) * | 2020-11-19 | 2022-05-27 | Tempus Labs, Inc. | Determination of cytotoxic gene signature and associated systems and methods for response prediction and treatment |
| CN112530581B (zh) * | 2020-12-03 | 2023-11-21 | 安徽医科大学第一附属医院 | 一种前列腺癌患者的免疫分子分类系统及其应用 |
| EP4026918A1 (en) | 2021-01-12 | 2022-07-13 | Koninklijke Philips N.V. | Prediction of an outcome of a colorectal cancer subject |
| CN112831562A (zh) * | 2021-01-25 | 2021-05-25 | 浙江科技学院 | 一种用于预测肝癌患者切除术后复发风险的生物标志物组合、试剂盒 |
| IL306090A (en) * | 2021-03-25 | 2023-11-01 | Oncxerna Therapeutics Inc | Targeted cancer treatments |
| WO2022211620A1 (en) * | 2021-04-01 | 2022-10-06 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Cd4/il-2 biomarker. |
| EP4370713A1 (en) | 2021-07-15 | 2024-05-22 | Vib Vzw | Biomarkers predicting response of breast cancer to immunotherapy |
| JP7480754B2 (ja) | 2021-07-19 | 2024-05-10 | トヨタ自動車株式会社 | 蓄電装置 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| EP4526470A1 (en) * | 2022-05-19 | 2025-03-26 | Agendia N.V. | Prediction of response to immune therapy in breast cancer patients |
| IL317449A (en) | 2022-06-07 | 2025-02-01 | Genentech Inc | Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist |
| KR20240051492A (ko) * | 2022-10-13 | 2024-04-22 | 주식회사 네오셀라 | 대식세포 분화 및 분포에 따른 면역세포 치료제의 치료 반응성 예측 방법 |
| AU2024230918A1 (en) | 2023-03-06 | 2025-10-16 | Genentech, Inc. | Prognostic and therapeutic methods for non-small cell lung cancer |
| WO2024225488A1 (ja) * | 2023-04-27 | 2024-10-31 | 株式会社リプロセル | 抗ｐｄ－１抗体療法に応答性である候補がん患者を同定する方法 |
| WO2024234348A1 (en) * | 2023-05-17 | 2024-11-21 | Yanjun Wang | Biomarker for immune checkpoint blockade therapy in nsclc |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| WO1991003489A1 (en) | 1989-09-08 | 1991-03-21 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| PT659439E (pt) | 1993-12-24 | 2002-04-29 | Merck Patent Gmbh | Imunoconjugados |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| EP0772609B1 (en) | 1994-07-21 | 1999-02-24 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| EP2163546B1 (en) | 1995-03-30 | 2016-06-01 | Pfizer Products Inc. | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| TR199800012T1 (xx) | 1995-07-06 | 1998-04-21 | Novartis Ag | Piroloprimidinler ve preparasyon i�in tatbikler. |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| DE69710712T3 (de) | 1996-04-12 | 2010-12-23 | Warner-Lambert Co. Llc | Umkehrbare inhibitoren von tyrosin kinasen |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| HUP0004286A3 (en) | 1997-11-06 | 2002-01-28 | American Cyanamid Co Madison | Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps |
| JP3687900B2 (ja) | 1998-11-19 | 2005-08-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | チロシンキナーゼの不可逆的阻害剤であるｎ−［４−（３−クロロ−４−フルオロフェニルアミノ）−７−（３−モルホリン−４−イルプロポキシ）キナゾリン−６−イル］アクリルアミド |
| JP5883384B2 (ja) * | 2009-08-13 | 2016-03-15 | ザ ジョンズ ホプキンス ユニバーシティー | 免疫機能を調節する方法 |
| GB0917457D0 (en) * | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
| WO2011040532A1 (ja) * | 2009-10-02 | 2011-04-07 | 学校法人 久留米大学 | 癌患者に対する免疫療法の治療効果および／または免疫療法後の予後の予測方法、ならびに該方法に用いる遺伝子セットおよびキット |
| US9404926B2 (en) * | 2010-01-29 | 2016-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
| WO2011130624A2 (en) | 2010-04-16 | 2011-10-20 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| WO2012016332A1 (en) * | 2010-08-04 | 2012-02-09 | Med Biogene Inc. | Prognostic gene signatures for non-small cell lung cancer |
| KR20190133790A (ko) * | 2011-08-01 | 2019-12-03 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
| EP2615181A1 (en) * | 2012-01-10 | 2013-07-17 | Universite Joseph Fourier - Grenoble 1 | Cyclon expression for the identification and control of cancer cells |
| SG10201700698WA (en) * | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| WO2014023706A1 (en) * | 2012-08-06 | 2014-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for screening patients with a cancer |
| EP2920325A2 (en) * | 2012-11-15 | 2015-09-23 | Bristol-Myers Squibb Company | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent |
-
2015
- 2015-12-29 CN CN201580070110.8A patent/CN107208138A/zh active Pending
- 2015-12-29 WO PCT/US2015/067878 patent/WO2016109546A2/en not_active Ceased
- 2015-12-29 EP EP15832855.9A patent/EP3240908A2/en active Pending
- 2015-12-29 JP JP2017534648A patent/JP2018503373A/ja active Pending
-
2017
- 2017-05-31 US US15/609,473 patent/US11236394B2/en active Active
-
2021
- 2021-03-01 JP JP2021031306A patent/JP7325463B2/ja active Active
- 2021-12-17 US US17/554,966 patent/US12385098B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503373A5 (enExample) | ||
| Fridman et al. | Tertiary lymphoid structures and B cells: An intratumoral immunity cycle | |
| Gavrielatou et al. | Biomarkers for immunotherapy response in head and neck cancer | |
| JP7430136B2 (ja) | 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物 | |
| Jin et al. | CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers | |
| RU2017119231A (ru) | Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40 | |
| JP6815992B2 (ja) | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 | |
| JP2017536842A5 (enExample) | ||
| Badoual et al. | PD-1–expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer | |
| US20220332823A1 (en) | Methods of treating cancer | |
| JP2024059707A (ja) | 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療 | |
| Grenga et al. | Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis | |
| EP4104187A1 (en) | Method of predicting response to chimeric antigen receptor therapy | |
| JP2023508947A (ja) | 循環腫瘍ｄｎａの分析を介した分子疾患評価のための方法およびシステム | |
| CN112805378A (zh) | 用于评估整合核酸的方法 | |
| WO2019036724A2 (en) | CELLULAR THERAPIES TARGETING MOLECULAR MEDIATORS ASSOCIATED WITH DISEASE, FIBROUS, INFLAMMATORY, AND AUTOIMMUNE CONDITIONS | |
| JP2023516954A (ja) | 遺伝子サンプリングにおける統計的バイアスの軽減 | |
| CN113710274A (zh) | 用于预测癌症免疫疗法中的长期存活的方法及组合物 | |
| Guo et al. | Transcriptome deconvolution reveals absence of cancer cell expression signature in immune checkpoint blockade response | |
| US20250140406A1 (en) | Classifying tumors and predicting responsiveness | |
| Wagner et al. | Conserved programs and specificities of T cells targeting hematological malignancies | |
| Le et al. | TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas | |
| US20240191310A1 (en) | Methods of determining cancer therapy effectiveness | |
| Mestrallet | Immune response and resistance of clear cell renal cell carcinoma patients following immune checkpoint blockade | |
| Scholz et al. | 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) |